GlassScriptPhysician profile
Kyle W Taylor
NPI 1245793231
$2,337.75
in general payments reported to CMS, 2019-2025
19 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $79.19 · 2022: $89.56 · 2023: $562 · 2024: $891 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $462.06 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $440.47 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $168.63 | 2023-2025 | Vraylar |
| Pfizer INC. | $168.15 | 2020-2025 | |
| Glaxosmithkline, LLC. | $163.54 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Idorsia Pharmaceuticals US INC | $156.57 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.23 | 2020 | |
| Lilly USA, LLC | $110.55 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $106.57 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $104.80 | 2023-2025 | Gardasil 9, Capvaxive, Belsomra |
| Astellas Pharma US INC | $95.37 | 2023-2024 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $61.04 | 2022-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $41.65 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $40.42 | 2024 | Voquezna |
| Dexcom, INC. | $37.76 | 2023-2024 | Dexcom G6 Transmitter |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.98 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.49 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.81 | 2021 | |
| Corcept Therapeutics | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.